Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate
• Assess the effects of poly-specific cytochrome P450 and drug-transporter induction by repeated dose Rifampicin (600 mg/day) co-administration on the single-dose pharmacokinetics of Neramexane.
• To assess safety and tolerability of Neramexane single dose treatment alone and co-administration of a Neramexane single dose with a Rifampicin repeated dose treatment.
|Study Design:||Masking: None (Open Label)|
|Official Title:||A Single Center, Open-Label, Three Periods, Fixed Sequence Design Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00955760
|AAIPharma Deutschland gmbH & Co. KG|
|Neu-Ulm, Bayern, Germany, 89231|